Objective: To document the impact on patient-reported outcomes and health-related quality of life (HRQoL) of treatment with imiquimod cream in patients with actinic keratosis (AK) and superficial basal cell carcinoma (sBCC). Methods: This open-label, multicenter study included AK and sBCC patients eligible for treatment with imiquimod 5% cream. HRQoL was measured by the Skindex-17 and the Skin Cancer Index (SCI) and treatment satisfaction by the Treatment Satisfaction Questionnaire for Medication. Results: 118 AK patients and 84 patients with sBCC were included. Low baseline HRQoL impairment was found on both questionnaires, which remained low after treatment, except for a small dip at the end of the application period. Conclusion: Imiquimod 5% cream treatment has no clinically relevant HRQoL impact in AK and sBCC patients according to the Skindex-17 and SCI. The effect of imiquimod treatment on HRQoL may be limited or these questionnaires do not fully capture relevant issues, such as fear of recurrence.

, , , , ,
doi.org/10.1159/000381420, hdl.handle.net/1765/83012
Dermatology: international journal for clinical and investigative dermatology
Department of Dermatology

Waalboer-Spuij, R, Holterhues, C, van Hattem, S, Schuttelaar, M.L.A, Gaastra, M.T.W, Kuijpers, D.I.M, … Nijsten, T.E.C. (2015). Patient Perception of Imiquimod Treatment for Actinic Keratosis and Superficial Basal Cell Carcinoma in 202 Patients. Dermatology: international journal for clinical and investigative dermatology, 231(1), 56–62. doi:10.1159/000381420